Study to evaluate hm15211 in patients with Nash (H-48721)
Description
Content
A phase 2, randomized, double-blind, placebo- controlled, parallel group study to evaluate efficacy, safety and tolerability of hm15211 treatment for 12 months in subjects with biopsy confirmed Nash.
Contact
Phone 1: 713–798–1037
IRB: H-48721
Status:
Active
Created:
